P. Carson, C. Flanagan, C. Ickes, and A. Alving, Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes, Science, vol.124, issue.3220, pp.484-485, 1956.
DOI : 10.1126/science.124.3220.484-a

R. Howes, F. Piel, A. Patil, O. Nyangiri, P. Gething et al., G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map, PLoS Medicine, vol.10, issue.11, pp.6-1001339, 2012.
DOI : 10.1371/journal.pmed.1001339.s010

J. Baird and C. Surjadjaja, Consideration of ethics in primaquine therapy against malaria transmission, Trends in Parasitology, vol.27, issue.1, pp.11-16, 2011.
DOI : 10.1016/j.pt.2010.08.005

J. Baird, Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria, Clinical Microbiology Reviews, vol.26, issue.1, pp.36-57, 2013.
DOI : 10.1128/CMR.00074-12

J. Baird, Reinventing primaquine for endemic malaria, Expert Opinion on Emerging Drugs, vol.94, issue.3, pp.439-444
DOI : 10.1186/1475-2875-10-212

N. White, The role of anti-malarial drugs in eliminating malaria, Malaria Journal, vol.7, issue.Suppl 1, p.8, 2008.
DOI : 10.1186/1475-2875-7-S1-S8

N. White, Determinants of relapse periodicity in Plasmodium vivax malaria, Malaria Journal, vol.10, issue.1, p.297, 2011.
DOI : 10.1371/journal.pone.0009047

T. Bousema and C. Drakeley, Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination, Clinical Microbiology Reviews, vol.24, issue.2, pp.377-410, 2011.
DOI : 10.1128/CMR.00051-10

N. White, Primaquine to prevent transmission of falciparum malaria, The Lancet Infectious Diseases, vol.13, issue.2, pp.175-181, 2012.
DOI : 10.1016/S1473-3099(12)70198-6

N. White, L. Qiao, G. Qi, and L. Luzzatto, Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common, Malaria Journal, vol.11, issue.1, p.418, 2012.
DOI : 10.1016/S0140-6736(10)61963-0

R. Maude, D. Socheat, C. Nguon, P. Saroth, P. Dara et al., Optimising Strategies for Plasmodium falciparum Malaria Elimination in Cambodia: Primaquine, Mass Drug Administration and Artemisinin Resistance, PLoS ONE, vol.201, issue.5, p.37166, 2012.
DOI : 10.1371/journal.pone.0037166.s008

L. Greene, G6PD deficiency as protection againstfalciparum malaria: An epidemiologic critique of population and experimental studies, American Journal of Physical Anthropology, vol.35, issue.S17, pp.153-178, 1993.
DOI : 10.1002/ajpa.1330360609

D. Kwiatkowski, How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria, The American Journal of Human Genetics, vol.77, issue.2, pp.171-192, 2005.
DOI : 10.1086/432519

E. Beutler, G6PD: Population genetics and clinical manifestations, Blood Reviews, vol.10, issue.1, pp.45-52, 1996.
DOI : 10.1016/S0268-960X(96)90019-3

I. Mueller, M. Galinski, J. Baird, J. Carlton, D. Kochar et al., Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite, The Lancet Infectious Diseases, vol.9, issue.9, pp.555-566, 2009.
DOI : 10.1016/S1473-3099(09)70177-X

M. Cappellini and G. Fiorelli, Glucose-6-phosphate dehydrogenase deficiency, The Lancet, vol.371, issue.9606, pp.64-74, 2008.
DOI : 10.1016/S0140-6736(08)60073-2

R. Howes, K. Battle, A. Satyagraha, J. Baird, and S. Hay, deficiency: Global distribution, genetic variants and primaquine therapy, p.6

C. Murray, T. Vos, R. Lozano, M. Naghavi, A. Flaxman et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990???2010: a systematic analysis for the Global Burden of Disease Study 2010, Disabilityadjusted life years (DALYs) for 291 diseases and injuries in 21 regions, pp.2197-2223, 1990.
DOI : 10.1016/S0140-6736(12)61689-4
URL : https://hal.archives-ouvertes.fr/hal-00827610

R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, The Lancet, vol.380, issue.9859, pp.2095-2128, 2010.
DOI : 10.1016/S0140-6736(12)61728-0
URL : https://hal.archives-ouvertes.fr/hal-00827612

M. Lacerda, S. Fragoso, M. Alecrim, M. Alexandre, B. Magalhaes et al., Postmortem Characterization of Patients With Clinical Diagnosis of Plasmodium vivax Malaria: To What Extent Does This Parasite Kill?, Clinical Infectious Diseases, vol.55, issue.8, pp.67-74, 2012.
DOI : 10.1093/cid/cis615

L. Luzzatto, D. Nathan, D. Ginsburg, A. Look, D. Fisher et al., Glucose-6-phosphate dehydrogenase deficiency In Nathan and Oski' s Hematology of Infancy and Childhood, 2009.

A. Minucci, K. Moradkhani, M. Hwang, C. Zuppi, B. Giardina et al., Glucose-6-phosphate dehydrogenase (G6PD) mutations database: Review of the ???old??? and update of the new mutations, Blood Cells, Molecules, and Diseases, vol.48, issue.3, pp.154-165, 2012.
DOI : 10.1016/j.bcmd.2012.01.001

P. Mason and T. Vulliamy, Glucose-6-phosphate dehydrogenase (G6PD) deficiency: genetics.I nEncyclopedia of Life Sciences, 2005.
DOI : 10.1002/9780470015902.a0006084.pub2

A. Yoshida, E. Beutler, and A. Motulsky, Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ, pp.243-253, 1971.

R. Hockwald, J. Arnold, and C. Clayman, 4. TOXICITY OF PRIMAQUINE IN NEGROES, JAMA: The Journal of the American Medical Association, vol.149, issue.17, pp.1568-1570, 1952.
DOI : 10.1001/jama.1952.72930340027010c

E. Beutler, Glucose-6-phosphate dehydrogenase deficiency, N Engl J Med, vol.324, pp.169-174, 1991.

R. Dern, E. Beutler, and A. Alving, The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character, J Lab Clin Med, vol.44, pp.171-176, 1954.

A. Alving, C. Johnson, A. Tarlov, G. Brewer, R. Kellermeyer et al., Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report, Bull World Health Organ, vol.22, pp.621-631, 1960.

L. Cavalli-sforza, P. Menozzi, and A. Piazza, The History and Geography of Human Genes, 1994.

S. Piomelli, L. Corash, D. Davenport, J. Miraglia, and E. Amorosi, In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and Gdmediterranean deficiency, Journal of Clinical Investigation, vol.47, issue.4, pp.940-948, 1968.
DOI : 10.1172/JCI105786

T. Meloni, G. Forteleoni, A. Dore, and S. Cutillo, Favism and Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase-Deficient Subjects in North Sardinia, Acta Haematologica, vol.70, issue.2, pp.83-90, 1983.
DOI : 10.1159/000206700

E. Beutler and S. Duparc, Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development, Am J Trop Med Hyg, vol.77, pp.779-789, 2007.

D. Clyde, Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug, Bull World Health Organ, vol.59, pp.391-395, 1981.

K. Buchachart, S. Krudsood, P. Singhasivanon, S. Treeprasertsuk, N. Phophak et al., Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand, Southeast Asian J Trop Med Public Health, vol.32, pp.720-726, 2001.

H. Matsuoka, J. Wang, M. Hirai, M. Arai, S. Yoshida et al., Glucose-6-phosphate dehydrogenase (G6PD) mutations in Myanmar: G6PD Mahidol (487G>A) is the most common variant in the Myanmar population, Journal of Human Genetics, vol.4, issue.10, pp.544-547, 2004.
DOI : 10.1007/s10038-004-0187-7

C. Louicharoen, E. Patin, R. Paul, I. Nuchprayoon, B. Witoonpanich et al., Positively Selected G6PD-Mahidol Mutation Reduces Plasmodium vivax Density in Southeast Asians, Science, vol.326, issue.5959, pp.1546-1549, 2009.
DOI : 10.1126/science.1178849

K. Burgoine, G. Bancone, and F. Nosten, The reality of using primaquine, Malaria Journal, vol.9, issue.1, p.376, 2010.
DOI : 10.1186/1475-2875-9-376

V. Laosombat, B. Sattayasevana, T. Chotsampancharoen, and M. Wongchanchailert, Glucose-6-Phosphate Dehydrogenase Variants Associated with Favism in Thai Children, International Journal of Hematology, vol.83, issue.2, pp.139-143, 2006.
DOI : 10.1532/IJH97.A20513

J. Baird, Elimination Therapy for the Endemic Malarias, Current Infectious Disease Reports, vol.48, issue.1, pp.227-237, 2012.
DOI : 10.1007/s11908-012-0250-z

P. Mason, J. Bautista, and F. Gilsanz, G6PD deficiency: the genotype-phenotype association, Blood Reviews, vol.21, issue.5, pp.267-283, 2007.
DOI : 10.1016/j.blre.2007.05.002

A. Mourant, A. Kopec, and K. Domaniewska-sobczak, The distribution of the human blood groups and other polymorphisms, 1976.

F. Livingstone, Frequencies of hemoglobin variants: thalassemia, the glucose- 6-phosphate dehydrogenase deficiency, G6PD variants and ovalocytosis in human populations, 1985.

E. Nkhoma, C. Poole, V. Vannappagari, S. Hall, and E. Beutler, The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis, Blood Cells, Molecules, and Diseases, vol.42, issue.3, pp.267-278, 2009.
DOI : 10.1016/j.bcmd.2008.12.005

S. Singh, Distribution of certain polymorphic traits in populations of the Indian peninsula and South Asia, Isr J Med Sci, vol.9, pp.1225-1237, 1973.

P. Gething, A. Patil, D. Smith, C. Guerra, I. Elyazar et al., A new world malaria map: Plasmodium falciparum endemicity in 2010, Malaria Journal, vol.10, issue.1, p.378, 2011.
DOI : 10.1186/1475-2875-10-378

P. Gething, I. Elyazar, C. Moyes, D. Smith, K. Battle et al., A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010, PLoS Neglected Tropical Diseases, vol.6, issue.9, p.1814, 2012.
DOI : 10.1371/journal.pntd.0001814.s004

S. Hay, C. Guerra, P. Gething, A. Patil, A. Tatem et al., A World Malaria Map: Plasmodium falciparum Endemicity in 2007, PLoS Medicine, vol.118, issue.3, p.1000048, 2007.
DOI : 10.1371/journal.pmed.1000048.sd009

K. Battle, P. Gething, I. Elyazar, C. Moyes, M. Sinka et al., The Global Public Health Significance of Plasmodium vivax, Adv Parasitol, vol.80, pp.1-111, 2012.
DOI : 10.1016/B978-0-12-397900-1.00001-3

S. Hay, C. Guerra, A. Tatem, A. Noor, and R. Snow, The global distribution and population at risk of malaria: past, present, and future, The Lancet Infectious Diseases, vol.4, issue.6, pp.327-336, 2004.
DOI : 10.1016/S1473-3099(04)01043-6

K. Mendis, B. Sina, P. Marchesini, and R. Carter, The neglected burden of Plasmodium vivax malaria, Am J Trop Med Hyg, vol.64, pp.97-106, 2001.

H. Singh, A. Parakh, S. Basu, and B. Rath, Plasmodium vivax malaria: Is it actually benign?, Journal of Infection and Public Health, vol.4, issue.2, pp.91-95, 2011.
DOI : 10.1016/j.jiph.2011.03.002

H. Mahgoub, G. Gasim, I. Musa, and I. Adam, Severe Plasmodium vivax malaria among sudanese children at New Halfa Hospital, Eastern Sudan, Parasites & Vectors, vol.5, issue.1, p.154, 2012.
DOI : 10.1128/AAC.05566-11

N. Douglas, F. Nosten, E. Ashley, L. Phaiphun, M. Van-vugt et al., Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics, Clinical Infectious Diseases, vol.52, issue.5, pp.612-620, 2011.
DOI : 10.1093/cid/ciq249

I. Harris, W. Sharrock, L. Bain, K. Gray, A. Bobogare et al., A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting, Malaria Journal, vol.9, issue.1, p.254, 2010.
DOI : 10.1186/1475-2875-9-254

A. Eziefula, R. Gosling, J. Hwang, M. Hsiang, T. Bousema et al., Rationale for short course primaquine in Africa to interrupt malaria transmission, Malaria Journal, vol.11, issue.1, p.360, 2012.
DOI : 10.1371/journal.pone.0005318

J. Edgcomb, J. Arnold, E. Yount, . Jr, A. Alving et al., Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report, J Natl Malar Soc, vol.9, pp.285-292, 1950.

A. Alving, D. Hankey, G. Coatney, R. Jones, . Jr et al., Korean vivax malaria. II. Curative treatment with pamaquine and primaquine, Am J Trop Med Hyg, vol.2, pp.970-976, 1953.

G. Coatney, A. Alving, R. Jones, . Jr, D. Hankey et al., Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency, Am J Trop Med Hyg, vol.2, pp.985-988, 1953.

C. Flanagan, S. Schrier, P. Carson, and A. Alving, The hemolytic effect of primaquine. VIII. The effect of drug administration on parameters of primaquine sensitivity, J Lab Clin Med, vol.51, pp.600-608, 1958.

E. Beutler, The hemolytic effect of primaquine and related compounds: a review, Blood, vol.14, pp.103-139, 1959.

A. Alving, B. Craige, T. Pullman, C. Whorton, R. Jones et al., PROCEDURES USED AT STATEVILLE PENITENTIARY FOR THE TESTING OF POTENTIAL ANTIMALARIAL AGENTS 1, Journal of Clinical Investigation, vol.27, issue.3 Pt 2, pp.2-5, 1948.
DOI : 10.1172/JCI101956

S. Shekalaghe, R. Ter-braak, M. Daou, R. Kavishe, W. Van-den-bijllaardt et al., In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A-) Individuals, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.1762-1768, 2010.
DOI : 10.1128/AAC.01135-09

L. Luzzatto, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics, The Lancet, vol.376, issue.9742, pp.739-741, 2010.
DOI : 10.1016/S0140-6736(10)60396-0

A. Pamba, N. Richardson, N. Carter, S. Duparc, Z. Premji et al., Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone, Blood, vol.120, issue.20, pp.4123-4133, 2012.
DOI : 10.1182/blood-2012-03-416032

S. Galiano, G. Gaetani, A. Barabino, F. Cottafava, H. Zeitlin et al., Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-)., BMJ, vol.300, issue.6719, p.236, 1990.
DOI : 10.1136/bmj.300.6719.236

A. Mehta, Glucose-6-phosphate dehydrogenase deficiency., Postgraduate Medical Journal, vol.70, issue.830, pp.871-877, 1994.
DOI : 10.1136/pgmj.70.830.871

T. Clark, A. Fry, S. Auburn, S. Campino, M. Diakite et al., Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility, European Journal of Human Genetics, vol.92, issue.8, pp.1080-1085, 2009.
DOI : 10.1086/320106

R. Howes, A. Patil, F. Piel, O. Nyangiri, C. Kabaria et al., The global distribution of the Duffy blood group, Nature Communications, vol.64, p.266, 2011.
DOI : 10.1038/ncomms1265
URL : https://hal.archives-ouvertes.fr/pasteur-00628295

M. Boyd, An Introduction to Malariology, The Journal of Parasitology, vol.17, issue.2, 1930.
DOI : 10.2307/3271445

C. Guerra, R. Howes, A. Patil, P. Gething, V. Boeckel et al., The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009, PLoS Neglected Tropical Diseases, vol.73, issue.8, p.774, 2009.
DOI : 10.1371/journal.pntd.0000774.s004

J. Ryan, J. Stoute, J. Amon, R. Dunton, R. Mtalib et al., Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya, Am J Trop Med Hyg, vol.75, pp.575-581, 2006.

R. Culleton, M. Ndounga, F. Zeyrek, C. Coban, P. Casimiro et al., in the Republic of the Congo, West Central Africa, The Journal of Infectious Diseases, vol.200, issue.9, pp.1465-1469, 2009.
DOI : 10.1086/644510

D. Menard, C. Barnadas, C. Bouchier, C. Henry-halldin, L. Gray et al., Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people, Proceedings of the National Academy of Sciences, vol.107, issue.13, pp.5967-5971, 2010.
DOI : 10.1073/pnas.0912496107
URL : https://hal.archives-ouvertes.fr/pasteur-00741118

C. Mendes, F. Dias, J. Figueiredo, V. Mora, J. Cano et al., Duffy Negative Antigen Is No Longer a Barrier to Plasmodium vivax ??? Molecular Evidences from the African West Coast (Angola and Equatorial Guinea), PLoS Neglected Tropical Diseases, vol.19, issue.2, p.1192, 2011.
DOI : 10.1371/journal.pntd.0001192.s001

N. Wurtz, M. Lekweiry, K. Bogreau, H. Pradines, B. Rogier et al., Vivax malaria in Mauritania includes infection of a Duffy-negative individual, Malaria Journal, vol.10, issue.1, p.336, 2011.
DOI : 10.1002/(SICI)1520-6300(199911/12)11:6<745::AID-AJHB4>3.0.CO;2-W

R. Feachem, A. Phillips, J. Hwang, C. Cotter, B. Wielgosz et al., Shrinking the malaria map: progress and prospects, The Lancet, vol.376, issue.9752, pp.1566-1578, 2010.
DOI : 10.1016/S0140-6736(10)61270-6

C. Cotter, H. Sturrock, M. Hsiang, J. Liu, A. Phillips et al., The changing epidemiology of malaria elimination: new strategies for new challenges, The Lancet, vol.382, issue.9895, pp.382900-911
DOI : 10.1016/S0140-6736(13)60310-4

S. Hay, P. Gething, and R. Snow, India's invisible malaria burden, The Lancet, vol.376, issue.9754, pp.1716-1717, 2010.
DOI : 10.1016/S0140-6736(10)61084-7

M. Manske, O. Miotto, S. Campino, S. Auburn, J. Almagro-garcia et al., Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing, Nature, vol.487, issue.7407, pp.375-379, 2012.
DOI : 10.1186/1471-2164-13-1

R. Takeuchi, S. Lawpoolsri, M. Imwong, J. Kobayashi, J. Kaewkungwal et al., Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border, Malaria Journal, vol.9, issue.1, p.308, 2010.
DOI : 10.1186/1475-2875-9-308

M. Phone, K. Myint, O. Aung, and N. , Aye Lwin H: The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar, Southeast Asian J Trop Med Public Health, vol.25, pp.710-713, 1994.

J. Song, D. Socheat, B. Tan, P. Dara, C. Deng et al., Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine, Malaria Journal, vol.9, issue.1, p.57, 2010.
DOI : 10.1186/1475-2875-9-57